MET as a possible target for non-small-cell lung cancer.
about
Molecular biology of lung cancerPatterns of Chromosomal Aberrations in Solid TumorsResponse to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingPharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRMechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerExpression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patientsMultiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASImplementation of biomarker-driven cancer therapy: existing tools and remaining gaps.Molecular pathology of lung cancer: current status and future directionsIn-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery.The non-coding RNAs of the H19-IGF2 imprinted loci: a focus on biological roles and therapeutic potential in Lung Cancer.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated DegradationNovel Role for γ-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1).Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.Nicotine enhances hepatocyte growth factor-mediated lung cancer cell migration by activating the α7 nicotine acetylcholine receptor and phosphoinositide kinase-3-dependent pathwayPersonalizing therapy in advanced non-small cell lung cancerGene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure.Clinical Challenges to Current Molecularly Targeted Therapies in Lung CancerTreatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorMET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis.Radionuclide imaging of drug delivery for patient selection in targeted therapy.Prognostic and predictive biomarkers in lung cancer. A review.Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.Targeting the oncogenic Met receptor by antibodies and gene therapy.Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Targeting the MET pathway for potential treatment of NSCLC.Prognostic and predictive value of MET deregulation in non-small cell lung cancerRan GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.
P2860
Q24606677-E6545A8C-D6A1-4B28-8390-E611C6F750F3Q26786127-769E9A8A-360A-4087-8163-1F027D9EAF84Q27853167-6D86D9FB-34B1-47B3-AC85-48ACE779E3C1Q28080730-7AF52475-63D8-4210-824E-820707C0F8C0Q28086993-2EB2AA10-B51E-46D8-809D-444097D910ACQ28547446-D1961033-987A-4512-8F4F-B1D1AA8B507CQ33688558-2AA62CA9-F34E-4F4E-B1DC-2ED5B5E8710BQ33688612-D0B485C3-3D7D-4A6B-9AF2-84A17C1614FDQ33757138-6CB16FC1-AB38-4CD4-87F0-D3428FD072ABQ33823276-CEEC9B65-F064-4980-B684-18DB53331BF7Q33830522-CEF85F1E-DAA1-4F41-8BEE-C97E6304DDFFQ34023414-E0D2F94B-710C-43ED-9840-CEC2B117B130Q34163458-AFF920CB-690C-4895-A385-153DFED64E70Q34194997-07E76C91-F519-4403-80E9-F38708CF1890Q35325715-FCDA128F-641A-462D-8833-26A799898E12Q35425128-1DF325AD-3717-47D0-9CF9-89F33BF7A78DQ35586700-36C682F9-9E2B-497E-AD8D-EC5B5DAE3129Q35632206-8E1E9E11-4B78-4F6F-8928-B766E915B3DCQ35800730-907E7DB0-3D43-4D25-8F5D-2B5CEFCB2CB9Q35860664-25528E73-2F57-4752-90A9-D900D7B6E692Q35955290-C4381318-2509-4338-B82C-71B942DFC575Q36502824-206F34AE-FF56-4629-B04E-120E53C37BA9Q36811453-B1CD9A92-5EA2-4527-9065-F3F92DA63D82Q36820341-B8DAE01A-1C14-4D72-BA17-968AB9A80AA4Q36972377-B34EA52C-9A5B-4A83-ADC2-F8EF2B84B0C6Q37011144-5E86EFAA-9595-4EC7-B743-3E0DF0F815BCQ37597858-3E74DA6B-53CA-48CD-ADE9-DC3D7C98C6C5Q37634419-360BC6BC-DD6D-42C4-92F1-D1B13993A1E4Q37721218-6D7A385F-CDA8-49CE-8FA4-C4BB9A07B007Q38132728-500028DF-F0BF-4270-BA21-836E3E69F429Q38176652-99D54E3E-AA5F-4C24-B79B-95400A216797Q38178187-2817904D-B104-4C5A-BF52-FB8F15E40848Q38213830-0E5CDD7E-EB32-43D8-BE02-EAD8FD512934Q38216590-F7FE274B-9E1B-42AC-BE31-6974E3194AECQ38258948-9C15B0E0-898D-46FF-B98D-42F91F8A9C9CQ38297235-F569AC55-386E-4D43-BFC5-2766AE464153Q38493294-DCDE4E00-3D42-4D95-BECD-570BD8CDC6EEQ38742042-C189A21D-047B-4E67-BDB3-AA628CE7FA6BQ38771978-FEABC8FA-0BB2-4AA7-B8FF-37855A7A9A28Q38869420-84643011-7B7E-4B48-8F33-582D2F99B22F
P2860
MET as a possible target for non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MET as a possible target for non-small-cell lung cancer.
@ast
MET as a possible target for non-small-cell lung cancer.
@en
type
label
MET as a possible target for non-small-cell lung cancer.
@ast
MET as a possible target for non-small-cell lung cancer.
@en
prefLabel
MET as a possible target for non-small-cell lung cancer.
@ast
MET as a possible target for non-small-cell lung cancer.
@en
P2860
P356
P1476
MET as a possible target for non-small-cell lung cancer.
@en
P2093
Ahad A Sadiq
P2860
P304
P356
10.1200/JCO.2012.43.9422
P407
P50
P577
2013-02-11T00:00:00Z